{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:31:01Z","timestamp":1793226661624,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018779","name":"Fero Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"Caixabank SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020636","name":"Spain Ministry of Education Vocational Training and Sports","doi-asserted-by":"publisher","award":["RYC2022-037005-I"],"award-info":[{"award-number":["RYC2022-037005-I"]}],"id":[{"id":"10.13039\/501100020636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmorw.2026.100721","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:33:11Z","timestamp":1782207191000},"page":"100721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Systematic identification of genomic nonresponse biomarkers to cancer therapies"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5820-9881","authenticated-orcid":false,"given":"J.","family":"Usset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-419X","authenticated-orcid":false,"given":"J.","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Roerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Roepman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-9542","authenticated-orcid":false,"given":"E.","family":"Cuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-1134","authenticated-orcid":false,"given":"F.","family":"Mart\u00ednez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmorw.2026.100721_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100721_bib2","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13643-024-02594-1","article-title":"Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research: an analysis of anticancer drugs versus supportive care in advanced esophageal cancer","volume":"13","author":"Santero","year":"2024","journal-title":"Syst Rev"},{"issue":"20","key":"10.1016\/j.esmorw.2026.100721_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.18.02067","article-title":"Rising and falling trends in the use of chemotherapy and targeted therapy near the end of life in older patients with cancer","volume":"37","author":"Fang","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41598-022-06239-y","article-title":"Co-occurrence CDK4\/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer","volume":"12","author":"Sitthideatphaiboon","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100721_bib6","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41588-025-02233-y","article-title":"Predicting resistance to chemotherapy using chromosomal instability signatures","volume":"57","author":"Thompson","year":"2025","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104112","article-title":"The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)","volume":"10","author":"Verkerk","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100721_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100124","article-title":"The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Galvano","year":"2021","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100721_bib9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-23-4027","article-title":"Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer","volume":"30","author":"van De Haar","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer","volume":"9","author":"Volders","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"19","key":"10.1016\/j.esmorw.2026.100721_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.esmorw.2026.100721_bib12","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1200\/OP.24.00226","article-title":"Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health system","volume":"20","author":"Dowdell","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10.1016\/j.esmorw.2026.100721_bib13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","article-title":"ESMO Recommendations on clinical reporting of genomic test results for solid cancers","volume":"35","author":"van de Haar","year":"2024","journal-title":"Ann Oncol"},{"issue":"7776","key":"10.1016\/j.esmorw.2026.100721_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery Protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.2016-0085","article-title":"Implementation of a multicenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies","volume":"22","author":"Bins","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100721_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7781","key":"10.1016\/j.esmorw.2026.100721_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmorw.2026.100721_bib20","author":"Vasimuddin"},{"key":"10.1016\/j.esmorw.2026.100721_bib21","author":"Watts"},{"key":"10.1016\/j.esmorw.2026.100721_bib22","series-title":"WiGiTS: Hartwig analysis pipeline","year":"2023"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"7964","key":"10.1016\/j.esmorw.2026.100721_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","article-title":"Pan-cancer whole-genome comparison of primary and metastatic solid tumours","volume":"618","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100721_bib26","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41588-024-01899-0","article-title":"Five latent factors underlie response to immunotherapy","volume":"56","author":"Usset","year":"2024","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100721_bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100721_bib30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100721_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","article-title":"Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"29","author":"van de Haar","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100721_bib32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ccell.2024.08.018","article-title":"Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer","volume":"42","author":"Cal\u00ec","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib33","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100721_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100721_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100721_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"23","key":"10.1016\/j.esmorw.2026.100721_bib37","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"6257","key":"10.1016\/j.esmorw.2026.100721_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100721_bib40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.esmorw.2026.100721_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.esmorw.2026.100721_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/bjc.2017.37","article-title":"Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer","volume":"116","author":"Jones","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100721_bib43","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:39:48Z","timestamp":1790264388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S2949820126000408"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100721","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic identification of genomic nonresponse biomarkers to cancer therapies","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100721"}}